For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Keros Therapeutics Inc’s stock clocked out at $18.43, down -73.15% from its previous closing price of $68.65. In other words, the price has decreased by -$73.15 from its previous closing price. On the day, 14.61 million shares were traded. KROS stock price reached its highest trading level at $19.32 during the session, while it also had its lowest trading level at $15.67.
Ratios:
To gain a deeper understanding of KROS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 2780828928 and an Enterprise Value of 235153552. For the stock, the TTM Price-to-Sale (P/S) ratio is 1148.54 while its Price-to-Book (P/B) ratio in mrq is 1.36. Its current Enterprise Value per Revenue stands at 361.219 whereas that against EBITDA is -1.159.
Stock Price History:
The Beta on a monthly basis for KROS is 1.20, which has changed by 1.1110086 over the last 52 weeks, in comparison to a change of 0.28924453 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $27.31. The 50-Day Moving Average of the stock is -69.27%, while the 200-Day Moving Average is calculated to be -66.71%.
Shares Statistics:
It appears that KROS traded 389.93K shares on average per day over the past three months and 443580 shares per day over the past ten days. A total of 39.26M shares are outstanding, with a floating share count of 30.20M. Insiders hold about 25.43% of the company’s shares, while institutions hold 79.02% stake in the company. Shares short for KROS as of 1732838400 were 2197295 with a Short Ratio of 5.64, compared to 1730332800 on 2412173. Therefore, it implies a Short% of Shares Outstanding of 2197295 and a Short% of Float of 7.39.
Earnings Estimates
The current assessment of Keros Therapeutics Inc (KROS) involves the perspectives of 10.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.23 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$0.11 and -$5.5 for the fiscal current year, implying an average EPS of -$4.68. EPS for the following year is -$4.11, with 10.0 analysts recommending between $2.06 and -$6.55.
